Increased serum interleukin‐17 levels in patients with myasthenia gravis
- 13 July 2011
- journal article
- Published by Wiley in Muscle & Nerve
- Vol. 44 (2), 278-280
- https://doi.org/10.1002/mus.22070
Abstract
It has been suggested that interleukin‐17 (IL‐17) plays a crucial role in the development of several autoimmune diseases. However, there are no data about the relationship between myasthenia gravis and IL‐17. The aim of this study was to measure the concentration of IL‐17 and determine whether levels depend on the severity of MG. Serum IL‐17 concentrations were measured in 25 patients. IL‐17 concentrations were higher in generalized MG compared with controls and correlated with anti‐acetylcholinesterase receptor antibody titers. Muscle Nerve, 2011This publication has 13 references indexed in Scilit:
- IL‐6: Regulator of Treg/Th17 balanceEuropean Journal of Immunology, 2010
- Research advancement in immunopathogenesis of myasthenia gravisNeuroscience Bulletin, 2010
- Current Views on the Roles of Th1 and Th17 Cells in Experimental Autoimmune EncephalomyelitisJournal of Neuroimmune Pharmacology, 2010
- Phenotypical and functional characterization of T helper 17 cells in multiple sclerosisBrain, 2009
- Disequilibrium of T helper type 1, 2 and 17 cells and regulatory T cells during the development of experimental autoimmune myasthenia gravisImmunology, 2009
- Interleukin 17 acts in synergy with B cell–activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosusNature Immunology, 2009
- Correlating extent of neuromuscular instability with acetylcholine receptor antibodiesMuscle & Nerve, 2009
- A Potential Role for B-Cell Activating Factor in the Pathogenesis of Autoimmune Myasthenia GravisArchives of Neurology, 2008
- Serum BAFF expression in patients with myasthenia gravisJournal of Neuroimmunology, 2008
- Function of circulating antibody to acetylcholine receptor in myasthenia gravisNeurology, 1978